{"id":"use-of-buprenorphine-with-fao-30-ome","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine binds with high affinity to mu-opioid receptors in the central nervous system, producing analgesia through partial agonism. When used in patients already taking opioids at doses greater than 30 OME (oral morphine equivalents), careful dose titration and monitoring are required due to the risk of overdose, respiratory depression, and potential opioid withdrawal. This represents a clinical dosing guideline rather than a distinct mechanism.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that provides analgesia and is used in opioid-dependent patients, with dose adjustment required when combined with other opioids exceeding 30 oral morphine equivalents.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:01.682Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain"},{"name":"Opioid use disorder (maintenance treatment)"}]},"trialDetails":[{"nctId":"NCT05910190","phase":"PHASE4","title":"Buprenorphine for Cancer Pain","status":"UNKNOWN","sponsor":"Fox Chase Cancer Center","startDate":"2022-08-10","conditions":"Cancer-Related Pain","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Use of buprenorphine with FAO > 30 OME","genericName":"Use of buprenorphine with FAO > 30 OME","companyName":"Fox Chase Cancer Center","companyId":"fox-chase-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial mu-opioid receptor agonist that provides analgesia and is used in opioid-dependent patients, with dose adjustment required when combined with other opioids exceeding 30 oral morphine equivalents. Used for Moderate to severe pain, Opioid use disorder (maintenance treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}